BR112021015940A2 - Anticorpo anti-bag2 e métodos de tratamento de câncer - Google Patents

Anticorpo anti-bag2 e métodos de tratamento de câncer Download PDF

Info

Publication number
BR112021015940A2
BR112021015940A2 BR112021015940-1A BR112021015940A BR112021015940A2 BR 112021015940 A2 BR112021015940 A2 BR 112021015940A2 BR 112021015940 A BR112021015940 A BR 112021015940A BR 112021015940 A2 BR112021015940 A2 BR 112021015940A2
Authority
BR
Brazil
Prior art keywords
antibody
seq
cancer
amino acid
acid sequence
Prior art date
Application number
BR112021015940-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Seong Jin Kim
Dong Woo Kang
Original Assignee
Medpacto, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190016347A external-priority patent/KR102172541B1/ko
Priority claimed from KR1020190016359A external-priority patent/KR102241558B1/ko
Application filed by Medpacto, Inc. filed Critical Medpacto, Inc.
Publication of BR112021015940A2 publication Critical patent/BR112021015940A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112021015940-1A 2019-02-12 2020-02-12 Anticorpo anti-bag2 e métodos de tratamento de câncer BR112021015940A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR1020190016347A KR102172541B1 (ko) 2019-02-12 2019-02-12 Bag2 항체를 이용한 암 진단용 조성물 및 이를 이용한 방법
KR10-2019-0016347 2019-02-12
KR10-2019-0016359 2019-02-12
KR1020190016359A KR102241558B1 (ko) 2019-02-12 2019-02-12 Bag2 폴리펩티드 또는 이의 단편에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
PCT/IB2020/051136 WO2020165794A1 (en) 2019-02-12 2020-02-12 Anti-bag2 antibody and methods of treating cancer

Publications (1)

Publication Number Publication Date
BR112021015940A2 true BR112021015940A2 (pt) 2021-10-05

Family

ID=72044199

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021015940-1A BR112021015940A2 (pt) 2019-02-12 2020-02-12 Anticorpo anti-bag2 e métodos de tratamento de câncer

Country Status (11)

Country Link
US (2) US12122822B2 (https=)
EP (2) EP3938788A4 (https=)
JP (4) JP7706154B2 (https=)
CN (2) CN114269779B (https=)
AU (1) AU2020222326B2 (https=)
BR (1) BR112021015940A2 (https=)
CA (1) CA3129748A1 (https=)
MX (1) MX2021009690A (https=)
SG (1) SG11202108140SA (https=)
WO (2) WO2020165797A1 (https=)
ZA (1) ZA202106551B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015940A2 (pt) * 2019-02-12 2021-10-05 Medpacto, Inc. Anticorpo anti-bag2 e métodos de tratamento de câncer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560537B2 (en) 2002-09-30 2009-07-14 Ludwig Institute For Cancer Research Human sarcoma-associated antigens
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
JP2008518629A (ja) 2004-11-08 2008-06-05 シェーリング コーポレイション Ｍｄｌ−１の腫瘍との関連およびその方法
US20060159681A1 (en) * 2004-12-14 2006-07-20 Functional Neuroscience Inc. Compositions and methods to inhibit cell loss by using inhibitors of BAG
EP2142670A1 (en) * 2007-04-05 2010-01-13 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of breast cancer
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
US20100204055A1 (en) * 2008-12-05 2010-08-12 Bonner-Ferraby Phoebe W Autoantibody detection systems and methods
ITMI20131351A1 (it) 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
JP6637290B2 (ja) * 2015-11-05 2020-01-29 武 永安 Ｃｋ１９に特異的なモノクローナル抗体およびこれを産生するハイブリドーマ、癌の検出キット、癌の検出方法および癌の転移の判定方法
EP3364190A1 (en) * 2017-02-20 2018-08-22 Panka Cancer Research AG Method of detecting cancer or cancer cells
KR102039624B1 (ko) * 2017-03-03 2019-11-01 재단법인 차세대융합기술연구원 BAG2 및 Cathepsin B 상호결합 억제 물질 스크리닝 방법
KR102230314B1 (ko) * 2017-10-24 2021-03-22 주식회사 메드팩토 혈액으로부터 암을 진단하는 방법
BR112021015940A2 (pt) * 2019-02-12 2021-10-05 Medpacto, Inc. Anticorpo anti-bag2 e métodos de tratamento de câncer

Also Published As

Publication number Publication date
JP2022521706A (ja) 2022-04-12
AU2020222326B2 (en) 2026-03-19
JP7747268B2 (ja) 2025-10-01
JP2025071090A (ja) 2025-05-02
CN114269779B (zh) 2025-05-09
EP3938788A4 (en) 2023-01-04
WO2020165794A1 (en) 2020-08-20
MX2021009690A (es) 2021-10-01
JP2022525843A (ja) 2022-05-20
CA3129748A1 (en) 2020-08-20
JP7706154B2 (ja) 2025-07-11
CN114269779A (zh) 2022-04-01
EP3924382A4 (en) 2023-01-04
CN114761803B (zh) 2025-09-05
ZA202106551B (en) 2024-12-18
JP2025071822A (ja) 2025-05-08
US20230183324A1 (en) 2023-06-15
CN114761803A (zh) 2022-07-15
EP3938788A1 (en) 2022-01-19
US20230194534A1 (en) 2023-06-22
US12583915B2 (en) 2026-03-24
WO2020165797A1 (en) 2020-08-20
EP3924382A1 (en) 2021-12-22
AU2020222326A1 (en) 2021-08-19
US12122822B2 (en) 2024-10-22
SG11202108140SA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
KR102618312B1 (ko) 항muc16 항체 및 그의 용도
TWI432452B (zh) 針對ｈｅｒ-３之抗體類及其用途
RU2623122C2 (ru) Моноклональные антитела и способы их применения
JP5570218B2 (ja) Ｆｇｆｒ４抗体
KR20190105024A (ko) 항-cd47 항체 및 그 용도
BR112020023844A2 (pt) Anticorpos, métodos de tratamento do câncer e de produção de um anticorpo, ácido nucleico, vetor, células hospedeiras e composição farmacêutica
KR20210013165A (ko) GUCY2c에 특이적인 항체 및 이의 용도
US20230398230A1 (en) Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
CN110914302A (zh) 可活化抗pdl1抗体及其使用方法
BR112019013238A2 (pt) Anticorpos anti-pd-1 e usos dos mesmos
CN115998901B (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
TW201106970A (en) Humanized anti-EGFL7 antibodies and methods using same
WO2021239026A1 (zh) 针对Claudin18.2的抗体及其用途
JP6449876B2 (ja) ニューレグリンに対して非競合的でアロステリックな抗ヒトｈｅｒ３抗体及びその使用
JP2025071822A (ja) 抗ｂａｇ２抗体および癌を治療する方法
TWI510249B (zh) 涉及突變之ｋｒａｓ或ｂｒａｆ基因之癌症的治療
US20090258020A1 (en) Antibody designated barb3, barb3 related antibodies, and methods of making and using same
WO2024109657A1 (zh) 抗ccr8抗体及其用途
TWI869582B (zh) 抗ｃｄ４７抗體及其用途
RU2815586C2 (ru) Антитело к bag2 и способы лечения онкологического заболевания
US20230416375A1 (en) Antibody variants against wnt receptor ryk
WO2023125652A1 (zh) 抗cd40×cldn18.2双特异性抗体及其用途
HK40091702A (en) Treatment for mesothelioma through administration of anti-b7-h3 antibody-drug conjugate
CN121419996A (zh) 用于治疗受试者的her2低表达肿瘤的抗her2抗体
EA045144B1 (ru) Лечение her2-мутированного рака введением конъюгата анти-her2-антитело-лекарственное средство

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]